Goldman Sachs Group Inc Protalix Bio Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 150,829 shares of PLX stock, worth $280,541. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150,829
Previous 102,178
47.61%
Holding current value
$280,541
Previous $151,000
122.52%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding PLX
# of Institutions
82Shares Held
10.6MCall Options Held
23.6KPut Options Held
95.4K-
Opaleye Management Inc. Boston, MA2.58MShares$4.8 Million0.96% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.32MShares$2.45 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL902KShares$1.68 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.52 Million0.0% of portfolio
-
Stratos Wealth Partners, Ltd.500KShares$930,0000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $92.5M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...